Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with consolidative chemoradiotherapy and ablative stereotactic radiotherapy for oligometastatic extensive-stage small cell lung cancer
2024-517937-41-00Phase 2Authorised
- Sponsor
- Saarland University
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC), sponsored by Saarland University. Primary endpoint: One-year progression-free survival rate. Planned start Oct 2024; status: authorised.
02
Drugs
durvalumabetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-517937-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517937-41-00.